Top

Digestive Diseases and Sciences

Published in:

01-02-2018 | Review

Efficacy of ¹²⁵I Versus Non-¹²⁵I Combined with Transcatheter Arterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma with Obstructive Jaundice

Authors: Shuangxi Li, Xuewen He, Lei Dang, Fangyu Xu, Jin Fang, Fenqiang Li, Wenhui Wang

Published in: Digestive Diseases and Sciences | Issue 2/2018

Abstract

Purpose

To compare the therapeutic effects of ¹²⁵I versus non-¹²⁵I combined with transcatheter arterial chemoembolization (TACE) for the treatment of unresectable hepatocellular carcinoma (HCC) with obstructive jaundice.

Methods

A retrospective analysis was conducted using the records of 54 consecutive patients who were initially diagnosed with HCC with obstructive jaundice between May 2009 and July 2016. Twenty-one cases (group A) were treated with percutaneous transhepatic biliary drainage (PTBD) followed by ¹²⁵I radioactive seed strip implantation through the PTBD tube. After the total serum bilirubin level was reduced to normal and the liver function recovered to Child–Pugh class A or early B, TACE was conducted. In 33 cases (group B) PTBD was performed in combination with TACE without applying the ¹²⁵I radioactive seeds. The duration of biliary patency and survival were analyzed.

Results

The technical success rate in both groups was 100%. The median biliary patency time was 6.000 ± 0.315 months (95% CI 5.382–6.618 months) in group A and 4.000 ± 0.572 months (95% CI 2.879–5.121 months) in group B; the two groups were significantly different (P = 0.001). The median survival was 11.000 ± 0.864 months (95% CI 9.306–12.694 months) in group A and 9.000 ± 0.528 months (95% CI 7.965–10.035 months) in group B; the two groups were significantly different (P = 0.022).

Conclusions

The combination of 125I with TACE was more effective than TACE without the radioactive seeds for treating patients with unresectable HCC with obstructive jaundice. Future prospective trials with larger samples will be required to validate these results.

Mesci A, Gurer S, Guzel G, et al. Obstructive jaundice caused by hepatocellular carcinoma with bile duct tumor thrombi: a case report. Eurasian J Med. 2008;40:45–47.PubMedPubMedCentral

Minami Y, Kudo M. Hepatocellular carcinoma with obstructive jaundice: endoscopic and percutaneous biliary drainage. Dig Dis. 2012;30:592–597.CrossRefPubMed

Park S, Park JY, Chung MJ, et al. The efficacy of endoscopic palliation of obstructive jaundice in hepatocellular carcinoma. Yonsei Med J. 2014;55:1267–1272.CrossRefPubMedPubMedCentral

Choi J, Ryu JK, Lee SH, et al. Biliary drainage for obstructive jaundice caused by unresectable hepatocellular carcinoma: the endoscopic versus percutaneous approach. Hepatobiliary Pancreat Dis Int. 2012;11:636–642.CrossRefPubMed

Shiu W, Dewar G, Leung N, et al. Hepatocellular carcinoma in Hong Kong: clinical study on 340 cases. Oncology. 1990;47:241–245.CrossRefPubMed

Lau W, Leung K, Leung TW, et al. A logical approach to hepatocellular carcinoma presenting with jaundice. Ann Surg. 1997;225:281–285.CrossRefPubMedPubMedCentral

Cho HC, Lee JK, Lee KH, et al. Are endoscopic or percutaneous biliary drainage effective for obstructive jaundice caused by hepatocellular carcinoma? Eur J Gastroenterol Hepatol. 2011;23:224–231.CrossRefPubMed

Suh YG, Kim DY, Han KH, et al. Effective biliary drainage and proper treatment improve outcomes of hepatocellular carcinoma with obstructive jaundice. Gut Liver. 2014;8:526–535.CrossRefPubMedPubMedCentral

Park HC, Park HB, Chung CY, et al. Acute obstructive cholangitis complicated by tumor migration after transarterial chemoembolization: a case report and literature review. Korean J Gastroenterol. 2014;63:171–175.CrossRefPubMed

10.

Garcea G, Ong SL, Dennison AR, Berry DP, Maddern GJ. Palliation of malignant obstructive jaundice. Dig Dis Sci. 2009;54:1184–1198. https://doi.org/10.1007/s10620-008-0479-4.CrossRefPubMed

11.

Peng SY, Wang JW, Liu YB, et al. Surgical Intervention for obstructive jaundice due to biliary tumor thrombus in hepatocellular carcinoma. World J Surg. 2004;28:43–46.CrossRefPubMed

12.

Ahmed S, de Souza NN, Qiao W, et al. Quality of life in hepatocellular carcinoma patients treated with transarterial chemoembolization. HPB Surg. 2016;2016:6120143. https://doi.org/10.1155/2016/6120143.CrossRefPubMedPubMedCentral

13.

Park CK, Bae SH, Yang HJ, et al. Successful treatment of stereotactic body radiation therapy combined with transarterial chemolipiodolization for hepatocellular carcinoma with biliary obstruction. Korean J Intern Med. 2011;26:94–98.CrossRefPubMedPubMedCentral

14.

Choi J, Ryu JK, Lee SH, et al. Palliative treatment of unresectable hepatocellular carcinoma with obstructive jaundice using biliary drainage with subsequent transarterial chemoembolization. J Palliat Med. 2013;16:1026–1033.CrossRefPubMed

15.

Chengwu T, Jian S, Wenming F, et al. Combination therapy of radiofrequency ablation and transarterial chemoembolization for unresectable hepatocellular carcinoma. Medicine (Baltimore) 2016; 95: e3754. Published online 2016 May 20. https://doi.org/10.1097/md.0000000000003754.

16.

Jiao D, Xinwei H, Wang Y, et al. Y-configured metallic stent combined with ¹²⁵I seed strands cavity brachytherapy for a patient with type IV Klatskin tumor. J Contemp Brachytherapy. 2016; 8: 356–360. https://doi.org/10.5114/jcb.2016.61704.

17.

Wenhui LI, Zhenyu DAI, Lizheng YAO, et al. Chemoembolization and stenting combined with iodine-125 seed strands for the treatment of hepatocellular carcinoma with inferior vena cava obstruction. Exp Ther Med. 2015;10:973–977.CrossRef

18.

Kikuchi L, Oliveira A-S, et al. Hepatocellular carcinoma management in nonalcoholic fatty liver disease patients. Am J Clin Oncol. 2016;39:428–432.CrossRefPubMed

19.

Huang W-K, Yang S-F, You L-N, et al. Transcatheter arterial chemoembolisation (TACE) plus S-1 for the treatment of BCLC stage B hepatocellular carcinoma refractory to TACE. Contemp Oncol (Pozn). 2016;20:468–474.

20.

Huang M, Lin Q, Wang H, et al. Survival benefit of chemoembolization plus Iodine125 seed implantation in unresectable hepatitis B-related hepatocellular carcinoma with PVTT: a retrospective matched cohort study. Eur Radiol. 2016;26:3428–3436.CrossRefPubMedPubMedCentral

21.

Matsueda K, Yamamoto H, Umeoka F, et al. Effectiveness of endoscopic biliary drainage for unresectable hepatocellular carcinoma associated with obstructive jaundice. J Gastroenterol. 2001;36:173–180.CrossRefPubMed

22.

Lee JW, Han JK, Kim TK, et al. Obstructive jaundice in hepatocellular carcinoma: response after percutaneous transhepatic biliary drainage and prognostic factors. Cardiovasc Interv Radiol. 2002;25:176–179.CrossRef

23.

Zhang Y-F, Wei W, Wang J-H, et al. Transarterial chemoembolization combined with sorafenib for the treatment of hepatocellular carcinoma with hepatic vein tumor thrombus. Onco Targets Ther. 2016;9:4239–4246.CrossRefPubMedPubMedCentral

24.

Qin L-X, Tang Z-Y. Hepatocellular carcinoma with obstructive jaundice: diagnosis, treatment and prognosis. World J Gastroenterol. 2003;9:385–391.CrossRefPubMedPubMedCentral

25.

Bigot P, Buchanan GM, Hamy A, et al. Rupture of hepatocellular carcinoma into the biliary system with resulting bile duct thrombi: report of two cases. Case Rep Gastroenterol. 2007;1:123–129.CrossRefPubMedPubMedCentral

26.

Paik EK, Kim M-S, Jang WI, et al. Benefits of stereotactic ablative radiotherapy combined with incomplete transcatheter arterial chemoembolization in hepatocellular carcinoma. Radiat Oncol. 2016: 22. Published online 2016 Feb 19. https://doi.org/10.1186/s13014-016-0597-7.

27.

Ingold JA, Reed GB, Kaplan HS, Bagshaw MA. Radiation hepatitis. Am J Roentgenol Radium Ther Nucl Med. 1965;93:200–208.PubMed

28.

Pan CC, Kavanagh BD, Dawson LA, et al. Radiation-associated liver injury. Int J Radiat Oncol Biol Phys. 2010;76:S94–S100. https://doi.org/10.1016/j.ijrobp.2009.06.092.CrossRefPubMedPubMedCentral

29.

Marchal F, Elias D, Rauch P, et al. Prevention of biliary lesions that may occur during radiofrequency ablation of the liver. Ann Surg. 2006;243:82–88.CrossRefPubMedPubMedCentral

30.

Schmidt A, Bloechinger M, Weber A, et al. Short-term effects and adverse events of endoscopically applied radiofrequency ablation appear to be comparable with photodynamic therapy in hilar cholangiocarcinoma. United European Gastroenterol J. 2016;4:570–579.CrossRefPubMedPubMedCentral

31.

Yu X, Li J, Zhong X, et al. Combination of Iodine-125 brachytherapy and chemotherapy for locally recurrent stage III non-small cell lung cancer after concurrent chemoradiotherapy. BMC Cancer. 2015;15:656.CrossRefPubMedPubMedCentral

32.

Sacco R, Mismas V, Marceglia S, et al. Transarterial radioembolization for hepatocellular carcinoma: an update and perspectives. World J Gastroenterol. 2015;21:6518–6525.CrossRefPubMedPubMedCentral

33.

Kennedy AS, Coldwell D, Nutting C, et al. Resin 90Y-microsphere brachytherapy for unresectable colorectal liver metastases: modern USA experience. Int J Radiat Oncol Biol Phys. 2006;65:412–425.CrossRefPubMed

34.

Zhou ZG, Chen JB, Qiu HB, et al. Parecoxib prevents complications in hepatocellular carcinoma patients receiving hepatic transarterial chemoembolization: a prospective score-matched cohort study. Oncotarget. 2016;7:27938–27945.PubMedPubMedCentral

35.

Siriwardana RC, Niriella MA, Dassanayake AS, et al. Factors affecting post-embolization fever and liver failure after trans-arterial chemo-embolization in a cohort without background infective hepatitis—a prospective analysis. BMC Gastroenterol. 2015; 96. Published online 2015 Aug 4. https://doi.org/10.1186/s12876-015-0329-8.

36.

Wigmore SJ, Redhead DN, Thomson BN, et al. Postchemoembolisation syndrome–tumour necrosis or hepatocyte injury? Br J Cancer. 2003;89:1423–1427.CrossRefPubMedPubMedCentral

37.

Khan KN, Nakata K, Kusumoto Y, et al. Evaluation of nontumorous tissue damage by transcatheter arterial embolization for hepatocellular carcinoma. Cancer Res. 1991;51:5667–5671.PubMed

38.

Kecheng Xu, Niu Lizhi, Feng Mu, et al. Cryosurgery in combination with brachytherapy of iodine-125 seeds for pancreatic cancer. Gland Surg. 2013;2:91–99.

39.

Chuan-Xing L, Xu H, Bao-Shan H, et al. Efficacy of therapy for hepatocellular carcinoma with portal vein tumor thrombus: Chemoembolization and stent combined with iodine-125 seed. Cancer Biol Ther. 2011;10:865–871. https://doi.org/10.4161/cbt.12.10.17676.CrossRef

40.

Gao J, Zhang Q, Zhang J, et al. Radiofrequency ablation of the main lesion of hepatocellular carcinoma and bile duct tumor thrombus as a radical therapeutic alternative. Med (Baltimore). 2015;94:e1122. https://doi.org/10.1002/1097-0142(19940301)73:5<1335:AID-CNCR2820730505>3.0.CO;2-M.CrossRef

Title: Efficacy of 125I Versus Non-125I Combined with Transcatheter Arterial Chemoembolization for the Treatment of Unresectable Hepatocellular Carcinoma with Obstructive Jaundice
Authors: Shuangxi Li
Xuewen He
Lei Dang
Fangyu Xu
Jin Fang
Fenqiang Li
Wenhui Wang
Publication date: 01-02-2018
Publisher: Springer US
Published in: Digestive Diseases and Sciences / Issue 2/2018
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-017-4899-x

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2018

Endoscopic Submucosal Dissection of Early Gastric Cancer in Patients with Liver Cirrhosis

Endoscopic Therapy of Biliary Injury After Cholecystectomy

Improving the Quality of Inpatient Bowel Preparation for Colonoscopies

Proton Pump Inhibitors Independently Protect Against Early Allograft Injury or Chronic Rejection After Lung Transplantation

Effect of Post-Traumatic Stress Disorder on Cognitive Function and Covert Hepatic Encephalopathy Diagnosis in Cirrhotic Veterans

Growing Concerns: A 3-Year-Old Girl with Multiple Hepatic Masses and Gastrointestinal Bleeding

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials